BRPI0809971A2 - Derivados de piridina e pirimidina como antagosnistas de mglur2 - Google Patents

Derivados de piridina e pirimidina como antagosnistas de mglur2

Info

Publication number
BRPI0809971A2
BRPI0809971A2 BRPI0809971-5A2A BRPI0809971A BRPI0809971A2 BR PI0809971 A2 BRPI0809971 A2 BR PI0809971A2 BR PI0809971 A BRPI0809971 A BR PI0809971A BR PI0809971 A2 BRPI0809971 A2 BR PI0809971A2
Authority
BR
Brazil
Prior art keywords
antagosnists
mglur2
pyridine
pyrimidine derivatives
pyrimidine
Prior art date
Application number
BRPI0809971-5A2A
Other languages
English (en)
Inventor
Silvia Gatti Mcarthur
Juergen Wichmann
Thomas Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39457413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0809971(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0809971A2 publication Critical patent/BRPI0809971A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
BRPI0809971-5A2A 2007-04-02 2008-03-25 Derivados de piridina e pirimidina como antagosnistas de mglur2 BRPI0809971A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07105429 2007-04-02
PCT/EP2008/053460 WO2008119689A1 (en) 2007-04-02 2008-03-25 Pyridine and pyrimidine derivatives as mglur2 antagonists

Publications (1)

Publication Number Publication Date
BRPI0809971A2 true BRPI0809971A2 (pt) 2014-10-07

Family

ID=39457413

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0809971-5A2A BRPI0809971A2 (pt) 2007-04-02 2008-03-25 Derivados de piridina e pirimidina como antagosnistas de mglur2

Country Status (17)

Country Link
US (2) US8012986B2 (pt)
EP (1) EP2142527B1 (pt)
JP (1) JP5303544B2 (pt)
KR (1) KR101143152B1 (pt)
CN (1) CN101641346B (pt)
AR (1) AR065891A1 (pt)
AT (1) ATE493400T1 (pt)
AU (1) AU2008233956B2 (pt)
BR (1) BRPI0809971A2 (pt)
CA (1) CA2681733A1 (pt)
CL (1) CL2008000936A1 (pt)
DE (1) DE602008004236D1 (pt)
IL (1) IL200780A (pt)
MX (1) MX2009010505A (pt)
PE (1) PE20090103A1 (pt)
TW (1) TW200845999A (pt)
WO (1) WO2008119689A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010007604A (es) * 2008-01-11 2010-08-02 Novartis Ag Pirimidinas como inhibidores de cinasa.
EP2604602A4 (en) 2010-08-11 2013-12-18 Taisho Pharmaceutical Co Ltd HETEROARYLPYRAZOLDERIVAT
JP2014062047A (ja) * 2011-01-21 2014-04-10 Taisho Pharmaceutical Co Ltd ピラゾール誘導体
RU2616619C2 (ru) * 2011-09-21 2017-04-18 Селлзоум Лимитед Морфолино-замещенные производные мочевины или карбамата в качестве ингибиторов mtor
US10189825B2 (en) * 2012-02-08 2019-01-29 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
SG11201503192XA (en) 2012-10-23 2015-06-29 Hoffmann La Roche Mglu2/3 antagonists for the treatment of autistic disorders
WO2015162076A2 (en) 2014-04-23 2015-10-29 F. Hoffmann-La Roche Ag Mglu2/3 antagonists for the treatment of intellectual disabilities
CA2950952C (en) 2014-06-10 2023-01-10 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof
KR20190065246A (ko) 2016-07-29 2019-06-11 선오비온 파마슈티컬스 인코포레이티드 화합물 및 조성물 및 이들의 용도
CN116514761A (zh) 2016-07-29 2023-08-01 赛诺维信制药公司 化合物、组合物及其用途
SG11202000669VA (en) 2017-08-02 2020-02-27 Sunovion Pharmaceuticals Inc Isochroman compounds and uses thereof
EP3810585A1 (de) * 2018-06-22 2021-04-28 Bayer Aktiengesellschaft Herstellungsverfahren für trizyclische verbindungen
CA3130849A1 (en) 2019-03-14 2020-09-17 Sunovion Pharmaceuticals Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03007513A (es) 2001-02-21 2004-07-30 Nps Pharma Inc Compuestos heteropoliciclicos y su uso como antagonistas del receptor metabotropico de glutamato.
US20060194807A1 (en) 2003-04-03 2006-08-31 Cosford Nicholas D P Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
JP2006522137A (ja) * 2003-04-04 2006-09-28 メルク エンド カムパニー インコーポレーテッド 代謝型グルタミン酸受容体−5のジ−アリール置換ピロールモジュレーター
CN100445294C (zh) * 2003-11-04 2008-12-24 高砂香料工业株式会社 铂络合物及发光元件
US20060173048A1 (en) 2005-02-03 2006-08-03 Mcarthur Silvia G Imidazole derivatives
PT2001849E (pt) 2006-03-29 2015-02-05 Hoffmann La Roche Derivados de piridina e pirimidina como antagonistas de r2mglu
US20070236568A1 (en) 2006-04-11 2007-10-11 Metke Anthony R Method and system for communicating incident scene information

Also Published As

Publication number Publication date
US8415380B2 (en) 2013-04-09
KR101143152B1 (ko) 2012-05-08
CN101641346A (zh) 2010-02-03
JP5303544B2 (ja) 2013-10-02
MX2009010505A (es) 2009-10-19
DE602008004236D1 (de) 2011-02-10
IL200780A0 (en) 2010-05-17
AR065891A1 (es) 2009-07-08
ATE493400T1 (de) 2011-01-15
KR20090117902A (ko) 2009-11-13
AU2008233956B2 (en) 2013-05-02
IL200780A (en) 2013-01-31
AU2008233956A1 (en) 2008-10-09
US20080280924A1 (en) 2008-11-13
CN101641346B (zh) 2013-11-06
CL2008000936A1 (es) 2008-10-03
EP2142527A1 (en) 2010-01-13
TW200845999A (en) 2008-12-01
JP2010524852A (ja) 2010-07-22
US20110263615A1 (en) 2011-10-27
EP2142527B1 (en) 2010-12-29
PE20090103A1 (es) 2009-02-13
WO2008119689A1 (en) 2008-10-09
US8012986B2 (en) 2011-09-06
CA2681733A1 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
BRPI0809971A2 (pt) Derivados de piridina e pirimidina como antagosnistas de mglur2
BRPI0907435A2 (pt) Derivados de 5-flúor pirimidina
BRPI0922095A2 (pt) derivados de piridina e pirimidina como inibidores de fosfodiesterase 10
BRPI0921598A2 (pt) derivados de piridina e pirimidina como inibidores de fosfodiesterase 10
ES2465673T9 (es) Derivados de pirimidina
BRPI0914544A2 (pt) derivados de pirimidona substituídos
BRPI0818658A2 (pt) Derivados de piridina úteis como ativadores de glicoquinase
BRPI0810462A2 (pt) Derivados de quinolina-carboxamida como antagonistas de p2y12
SI2001849T1 (sl) Derivati piridina in pirimidina kot antagonisti mglur2
BRPI0813707A2 (pt) Derivados de pirimidinil-piridazinona
BRPI0820112A2 (pt) Derivados de isoxazol-piridina
BRPI0809992A2 (pt) Derivados de pirrolopirimidina
BRPI0820113A2 (pt) Derivados de isoxazolo-piridazina
BRPI0812155A2 (pt) derivados de espiroindolinona
BRPI0817935A2 (pt) Derivados de biarila
BRPI0817562A2 (pt) derivados de n-hidroxilsulfonamida como novos doadores de niltroxil fisiologicamente úteis
BR112012000763A2 (pt) derivados de piridin-4-ila
BRPI0812247A2 (pt) Derivados de piridazinona
BRPI0920496A2 (pt) derivados substituídos de pirimidina etriazina
BRPI0812518A2 (pt) Derivados de indazolamida
BRPI0814236A2 (pt) Derivados de quinazolinamida
BRPI0820649A2 (pt) Derivados de isoxazalo-pirazina
BRPI1016117A2 (pt) derivados de isoxazol-isoxazol e isoxasol-isotiazol.
BRPI0822058A2 (pt) Derivados de 5-oxo-3-pirrolidinacarboxamida como moduladores de p2x7
BRPI0811115A2 (pt) Compostos de heteroarilamida pirimidona

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]